sufficient funds until 2017 !
septic shock in the game ! market potential enormous !
The Company continues to expect that its cash balance, including the fair value of its marketable securities, will be sufficient for it to accomplish its corporate goals through fiscal year 2017.
Michael Jebsen, Chief Financial Officer, said: "We believe that our current capital will be sufficient to fund our levosimendan program in LCOS through a New Drug Application filing. We also remain in a strong position to proactively evaluate business development opportunities during calendar year 2015, including levosimendan’s expansion in septic shock and potential additional candidates that fit into our critical care pipeline strategy.”
News 
Market Data 
Discover 
